Kenvue (KVUE) 10-K Summary — Year Ended Dec 31, 2023
Kenvue's annual report covers its first year as a standalone company after separation from Johnson & Johnson. The filing discusses business operations, risks from the separation, and financial results.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
Kenvue's annual report covers its first year as a standalone company after separation from Johnson & Johnson. The filing discusses business operations, risks from the separation, and financial results.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$15.4B
Revenue reported for the fiscal year.
Operating income
$2.5B
Income from operations reported for the year.
Net income
$1.7B
Net income reported for the year.
Operating cash flow
$3.2B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jul 2, 2023 | $4B | n/a |
| Oct 1, 2023 | $3.9B | -2.4% |
| Dec 31, 2023 | $15.4B | +294.5% |
Business overview
Kenvue operates as a consumer health company with a diverse portfolio of brands. It focuses on brand marketing, product development and innovation, and manages a global supply chain. The company faces competition and is subject to regulations and seasonality.
Financial performance
For the reporting period, Kenvue reported revenue, operating income, net income, and operating cash flow. The financial direction reflects the initial period after becoming an independent public company.
Material risks
Kenvue faces risks related to its separation from Johnson & Johnson, including the possibility that expected strategic and financial benefits may not be fully realized. The company may experience a higher cost of capital and loss of corporate brand identity. Additionally, its liquidity depends on top-tier banking partners, and any disruption could adversely affect access to credit.
Liquidity and capital
The company's liquidity and capital resources are supported by relationships with top-tier banking partners for credit and supply chain finance. Disruptions to these partners could negatively impact cash flows.
What to watch
Investors should monitor the company's progress in achieving the anticipated benefits from its separation from Johnson & Johnson.